GlaxoSmithKline 4Q 4Q Revenues: $13.0 billion (+18%) 4Q Earnings: $2.7 billion (+80%) FY Revenues: $44.3 billion (-2%) FY Earnings: $8.8 billion (+1%) Comments: Vaccine sales were up 85% to $2.4 billion with flu pre-pandemic sales accounting for $1.3 billion in the quarter. Seretide/Advair sales were $2.2 billion (+10%). Relenza sales were $408 million, up from $19 million in 4Q08. Valtrex sales were down 38% to $368 million. Seroxat/Paxil sales were $225 million (-10%). Avodart s...